Published in Brain on October 17, 2005
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers | NCT02683863
Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT) | NCT03896217
Gray Matter Demyelination in Primary Progressive MS at 7T | NCT04977622
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Evidence for a two-stage disability progression in multiple sclerosis. Brain (2010) 2.63
Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain (2010) 2.61
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol (2009) 2.56
Disease-specific molecular events in cortical multiple sclerosis lesions. Brain (2013) 2.48
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
Multiple sclerosis. J Clin Invest (2012) 2.41
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol (2012) 2.32
Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis. JAMA Neurol (2015) 2.18
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain (2007) 1.94
NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain (2012) 1.82
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (2013) 1.79
Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry (2014) 1.65
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology (2012) 1.63
Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss. J Neurol (2008) 1.51
Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol (2014) 1.50
Cortical lesions in multiple sclerosis. Nat Rev Neurol (2010) 1.47
Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. Radiology (2014) 1.46
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol (2014) 1.46
Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain (2015) 1.46
Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain (2010) 1.45
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation (2010) 1.41
Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.41
3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler (2008) 1.39
Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol (2007) 1.39
Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol (2010) 1.37
Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep (2009) 1.37
Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol (2011) 1.35
Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain (2008) 1.34
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol (2010) 1.27
Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol (2012) 1.27
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2007) 1.25
Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol (2008) 1.25
Myelin water imaging reflects clinical variability in multiple sclerosis. Neuroimage (2011) 1.24
Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS. Neurology (2014) 1.24
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain (2012) 1.22
Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur Radiol (2008) 1.22
The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology (2010) 1.22
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One (2013) 1.21
What went wrong? The flawed concept of cerebrospinal venous insufficiency. J Cereb Blood Flow Metab (2013) 1.19
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol (2008) 1.16
A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology (2011) 1.16
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs (2009) 1.14
Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One (2008) 1.14
Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol (2011) 1.12
Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol (2008) 1.12
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm (2014) 1.11
The innate immune system in demyelinating disease. Immunol Rev (2012) 1.10
Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflammation (2006) 1.10
Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol (2010) 1.10
Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol (2013) 1.08
Absence of cortical demyelination in neuromyelitis optica. Neurology (2010) 1.07
Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol (2009) 1.07
Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology (2012) 1.07
MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry (2009) 1.07
Genetics and pathogenesis of multiple sclerosis. Semin Immunol (2009) 1.06
Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? J Neurol (2008) 1.05
JC virus agnoprotein inhibits in vitro differentiation of oligodendrocytes and promotes apoptosis. J Virol (2007) 1.05
The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol (2008) 1.05
White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab (2012) 1.04
Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol (2008) 1.03
Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03
Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology (2013) 1.02
Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 9.4 T. MAGMA (2008) 1.02
Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain (2010) 1.01
Normal-appearing white and grey matter damage in MS. A volumetric and diffusion tensor MRI study at 3.0 Tesla. J Neurol (2007) 1.01
Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target. Radiology (2012) 1.00
Progressive multiple sclerosis. Semin Immunopathol (2009) 1.00
Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol (2012) 1.00
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler (2015) 1.00
The immunopathophysiology of multiple sclerosis. Neurol Clin (2011) 0.99
Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler (2012) 0.99
Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. J Biomed Opt (2011) 0.99
A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis. Mult Scler (2011) 0.98
Brain leukocyte infiltration initiated by peripheral inflammation or experimental autoimmune encephalomyelitis occurs through pathways connected to the CSF-filled compartments of the forebrain and midbrain. J Neuroinflammation (2012) 0.98
A unified cell biological perspective on axon-myelin injury. J Cell Biol (2014) 0.98
In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique. Neuroimage (2010) 0.97
Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. J Magn Reson Imaging (2011) 0.97
An animal model of cortical and callosal pathology in multiple sclerosis. Brain Pathol (2010) 0.97
7 Tesla magnetic resonance imaging to detect cortical pathology in multiple sclerosis. PLoS One (2014) 0.97
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler (2013) 0.97
Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol (2009) 0.97
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96
Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol (2012) 0.96
Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) (2013) 0.96
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann Clin Transl Neurol (2014) 0.95
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J Neurosci (2011) 0.95
Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol (2011) 0.95
MicroRNAs and Multiple Sclerosis. Autoimmune Dis (2010) 0.94
Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain (2014) 0.94
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci (2007) 6.23
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol (2007) 5.83
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 3.38
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain (2009) 3.04
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med (2011) 3.00
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61
CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain (2009) 2.59
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Angiocentric glioma: report of clinico-pathologic and genetic findings in 8 cases. Am J Surg Pathol (2007) 2.48
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Disease-specific molecular events in cortical multiple sclerosis lesions. Brain (2013) 2.48
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Remyelination is extensive in a subset of multiple sclerosis patients. Brain (2006) 2.43
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest (2006) 2.32
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain (2002) 2.27
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Microglial phenotype: is the commitment reversible? Trends Neurosci (2006) 2.18
Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest (2006) 2.17
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med (2007) 2.16
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med (2009) 2.13
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol (2012) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol (2006) 2.02
Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr (2004) 2.01
The role of nitric oxide in multiple sclerosis. Lancet Neurol (2002) 2.00
Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00
Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage (2008) 1.98
Oxidative damage in multiple sclerosis lesions. Brain (2011) 1.95
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain (2007) 1.94
Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain (2009) 1.93
Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol (2008) 1.93
Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging (2006) 1.92
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90